Cipla Ltd.

75 articles with Cipla Ltd.

• Cipla Announces the Launch of Daptomycin for Injection, 500 mg/vial, Single-dose Vials (for Intravenous use only)

  9/26/2019

  Cipla Limited and its subsidiary Cipla USA, Inc., announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States.

• Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma

  9/18/2019

  Phase 2 clinical trial initiated and enrollment progressing across 24 sites

• InvaGen (a Cipla Subsidiary) Receives Final Approval for Generic Version of Pfizer's Lyrica® (Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg)

  7/22/2019

  InvaGen Pharmaceuticals, Inc., a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced the receipt of final approval for its Abbreviated New Drug Application for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration.

• Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole™

  4/15/2019

  Transaction marks Cipla's entry into specialty respiratory segment, building on inroads made into the specialty business in the recent past

• Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

  1/14/2019

  Bio-Thera intends to file for regulatory approval with the China National Medical Products Administration, the European Medicines Agency and the United States Food and Drug Administration in 2020.

• 

  Drugs That Are Likely to Fall Off the Patent Cliff This Year

  4/5/2018

  If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.

• American Cancer Society And Clinton Health Access Initiative Announce Collaborations With Pfizer And Cipla To Increase Access To Lifesaving Cancer Treatment In Africa

  6/20/2017

• India's Third Largest Drugmaker Cipla Freezes Pay for 300 to 400 Top Managers

  9/29/2016

• Cipla's Global CEO Subhanu Saxena Resigns; New Replacement Named

  8/15/2016

• Cipla Names Umang Vohra As MD & Global CEO; Samina Vaziralli Is Executive Vice-Chairman

  8/12/2016

• Cipla Announces Q1 FY17 Results Performance Reflects Continued Momentum In Key Markets And Improvement In Base EBITDA Margins

  8/12/2016

• Cipla Appoints Kedar Upadhye As Global Chief Financial Officer

  8/1/2016

• Cipla Joins Global Movement To Eliminate Viral Hepatitis By 2030

  7/28/2016

• Cipla To Launch South Africa’s First Biotech Manufacturing Facility

  7/8/2016

• Big Pharmas Like Cipla, Pfizer Among the 200 Under Inspection for Poor Drugs

  6/21/2016

• DCGI Gives Limited Approval To Market First Allogeneic Cell Therapy Product In India

  5/30/2016

• Cipla Completes Acquisition Of Generic Businesses In US

  3/18/2016

• Cipla Announces Q3 FY1516 Unaudited Consolidated Financial Results

  2/10/2016

• Cipla Release: CARE Reaffirms ‘CARE AAA / A1+’ Rating

  1/21/2016

• Cipla Release: The Medicines Patent Pool Signs First Sub-Licences For Hepatitis C Medicine Daclatasvir

  1/20/2016